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Abstract
Background: Platinum agents have shown demonstrable activity in the treatment of patients with platinum
resistant, recurrent ovarian cancer when delivered in a “dose-dense” fashion. However, the development of
thrombocytopenia limits the weekly administration of carboplatin to no greater than AUC 2. Paclitaxel has a well-
described platelet sparing effect however its use to explicitly provide thromboprotection in the context of dose
dense carboplatin has not been explored.
Methods: We treated seven patients with platinum resistant ovarian cancer who had previously received paclitaxel
or who had developed significant peripheral neuropathy precluding the use of further full dose weekly paclitaxel.
Results: We were able to deliver carboplatin AUC 3 and paclitaxel 20 mg/m
2 with no thrombocytopenia or
worsening of neuropathic side-effects, and with good activity.
Conclusions: We conclude that this regimen may be feasible and active, and could be formally developed as a
“platinum-focussed dose-dense scaffold” into which targeted therapies that reverse platinum resistance can be
incorporated, and merits further evaluation.
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Background
Ovarian cancer is the leading cause of death from gynae-
cologic malignancies in the United Kingdom, and is the
fourth most common cause of cancer mortality in
women [1]. Despite 70-80% overall response to initial
therapy, the majority of patients will experience disease
relapse and will require further chemotherapy [2,3].
Several therapeutic options are available and the decision
as to which therapy to commence is dependent on the
time from last platinum chemotherapy to decision to
treat, known as the platinum-free interval (PFI) [4,5]. The
PFI is a predictor of response not only to second-line
treatment with platinum-based chemotherapy but also
other active agents [6]. Stemming from the original paper
by Markmann and colleagues in 1991, patients who
relapse within 6 months are termed platinum resistant,
those who never respond platinum refractory and those
who relapse after more than one year platinum sensitive
[4]. The term partially sensitive has come into use more
recently to describe the patients with a PFI of 6 to 12
months. The probability of response to platinum rechal-
lenge increases with the PFI, from > 60% in patients
relapsing > 12 months since last platinum therapy to
below 10% in patients relapsing within 6 months [4].
There is increasing evidence, however, that by adminis-
tering platinum in a ‘dose-dense’ manner, resistance can
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response [7].
Dose intensity is defined as the amount of drug adminis-
tered per unit of time, and can be increased in a number
of ways [8]. Firstly, the dose delivered per cycle can be
increased (dose intensity), secondly, the dosing interval
can be reduced keeping the dose per cycle and overall
dose the same (dose densification), and finally both the
dosing interval can be reduced and the overall dose
increased (increased dose intensity, total dose, and dose
density) [9]. The concept of dose manipulation, in particu-
lar the delivery of dose dense chemotherapy is not novel
and has been extensively studied in a number of tumour
types in particular breast cancer where significant
improvements in both disease free survival and overall
survival have been reported [10]. More recently, use of
adjuvant dose dense weekly paclitaxel in combination with
conventional platinum has demonstrated significant
improvement in progression free survival and overall sur-
vival in ovarian cancer [11].
An u m b e ro fd i f f e r e n t‘dose-dense’ carboplatin and
paclitaxel regimens have been developed for the treatment
of both front line and recurrent ovarian cancer [7,12].
Common to all these studies is the development of neuro-
toxicity associated with weekly paclitaxel, the reported
incidence of grade 3/4 neurotoxicity ranging from 2-94%.
The development of neuropathy may have a negative
impact on the administered dose intensity and patients’
quality of life, an important consideration in this essen-
tially palliative population. Furthermore, platinum resis-
tant patients with existing peripheral neuropathy or other
co-morbidities such as diabetes mellitus are poor candi-
dates for dose dense approaches that utilise either cisplatin
or paclitaxel because of the risk of further deterioration of
their neurological symptoms.
In the context of dose dense therapy the role of taxanes
is twofold, firstly to impart a cytotoxic effect and secondly
to improve the feasibility of carboplatin delivery by utilis-
ing the platelet sparing effect of paclitaxel [13,14]. Clini-
cally, it is accepted that carboplatin given at AUC > 2
weekly is non-feasible due to development of dose-limiting
thrombocytopenia, whereas the addition of weekly pacli-
taxel, 70-90 mg/m
2, allows higher doses of carboplatin to
be delivered weekly [15-17]. However this dose dense
schedule sits close to the limits of feasibility, and may
reduce the ability to subsequently integrate targeted thera-
pies, directed at reversing platinum resistance. We there-
fore chose to deliver a lower but sufficient dose of
paclitaxel to prevent thrombocytopenia when delivering
dose dense platinum in order to minimise neuropathy in
those patients with co-morbidities such as diabetes or pre-
existing (or developing) taxane neuropathy.
In this paper, we hypothesised that the platelet sparing
effect of paclitaxel occurs at doses lower than that
required for response. Therefore, patients receiving
weekly dose dense therapy who developed neuropathy
necessitating the reduction of paclitaxel dose were
afforded the opportunity to continue chemotherapy at
reduced paclitaxel dose whilst maintaining platinum
dose density. We describe here a case series of patients
receiving dose dense weekly carboplatin AUC 3 with
paclitaxel 20 mg/m
2 day 1, 8, 15 q4 weekly where reduc-
tions in paclitaxel dose were required due to clinical
indication. We demonstrate that the addition of low
dose paclitaxel allows delivery of weekly dose dense car-
boplatin AUC 3 by maintaining platelet counts without
compromising dose dense carboplatin mediated tumour
response. We also discuss the concept of a platinum-
focussed dose dense “scaffold” that may allow the more
feasible integration of single or multiple targeted thera-
pies aimed at reversing platinum resistance specifically,
potentially bringing us closer to effective platinum resis-
tance reversal in the clinic.
Methods
Seven consecutive patients with platinum resistant epithe-
lial ovarian cancer (relapse < 6 months from last plati-
num), with grade ≥ 2 neuropathic symptoms at the time
of commencement of dose dense therapy or who devel-
oped neuropathy whilst receiving weekly combination car-
boplatin AUC 3 and paclitaxel 70 mg/m
2, were treated
with carboplatin (AUC 3) and paclitaxel (20 mg/m
2)a d m i -
nistered day 1, 8, 15 q4weekly. Patients were treated at the
Department of Medical Oncology, Hammersmith Hospi-
tal, London, between 2009 and 2010.
Baseline CT imaging of the chest, abdomen and pelvis
was carried out prior to the commencement of therapy
and after every 2 cycles (8 weeks). Carboplatin dose was
calculated by EDTA clearance [18]. Blood samples for full
blood count (FBC), biochemistry, liver function tests
(LFTs) and serum CA125 test were taken prior to the
commencement of therapy and before each treatment
cycle. Patients were reviewed weekly during treatment for
safety assessment. All safety evaluations were graded
according to the National Cancer Institute Common Toxi-
city Criteria version 2.0. Consent was obtained from
patients prior to the commencement of treatment. Ethics
for the retrospective case review was obtained prior to
data collection from the Northwick Park Hospital ethical
review board.
Results
Patient 1
Patient 1: 63 year old diagnosed with stage 3C, grade 3
papillary serous ovarian carcinoma following suboptimal
debulking surgery. She received 6 cycles of adjuvant car-
boplatin AUC 6 and paclitaxel 175 mg/m
2 (6/2002-11/
2002). She relapsed eight months later (7/2003) and was
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Page 2 of 9treated with 6 cycles of cisplatin 80 mg/m
2 and etopo-
side 120 mg/m
2 (7/2003-1/2004) achieving a partial
response. In 2004, she had a second relapse and received
6 cycles of single agent carboplatin AUC 6 to partial
response (1/2005-6/2005). She was commenced on
maintenance tamoxifen 20 mg daily from 7/2005-1/2007
until relapse when she was treated with 6 cycles of sin-
gle agent carboplatin (AUC 6) (1/2007-6/2007) to partial
response. Palliative radiotherapy was then administered
to a rectal mass (7/2007). After a PFI of 5 months she
developed disease relapse and commenced dose dense
chemotherapy, carboplatin AUC 3 and paclitaxel 75 mg/
m
2 d 1, 8 and 15 q28. Despite having a partial response
on CT imaging, paclitaxel was discontinued due to the
development of grade 2 peripheral neuropathy She
received 2 weeks of single agent carboplatin (AUC2) but
developed dose limiting thrombocytopenia (79 × 10
9/L)
resulting in two weeks dose delay. Low dose paclitaxel,
20 mg/m
2, was then introduced as a platelet-sparing
agent. The carboplatin dose was subsequently increased
to AUC 3 (week 7) and then AUC 4 (week 8 and 9).
She developed grade 2 thrombocytopenia requiring a
2 week delay. Carboplatin dose was reduced to AUC 3
and the patient completed 18 cycles of dose dense
therapy. Serum Ca125 levels decreased from 2332 to
564 U/mL during the course of treatment and her CT
confirmed partial response with a significant decrease in
the size and number of both subcapsular and intrahepa-
tic metastases (Figure 1). The patient did not experience
further thrombocytopenia and her neuropathic symp-
toms gradually improved whilst on treatment.
Patient 2
62 year old woman with stage 3C, grade 3 serous ovarian
adenocarcinoma diagnosed following optimal debulking
surgery in 2007 The patient received 6 cycles of adjuvant
chemotherapy with carboplatin AUC 6 and paclitaxel
175 mg/m
2 (4/2007-8/2007). Following a PFI of five
months she developed progressive disease, with bilateral
hydronephrosis requiring ureteric stents. She was com-
menced on weekly carboplatin AUC 3 and paclitaxel
75 mg/m
2, however her pre-existing grade 2 neuropathy
significantly worsened after 5 weekly cycles, and the pacli-
taxel dose was reduced to 20 mg/m
2. She completed 18
cycles of therapy with no episodes of thrombocytopenia
and without any further deterioration in her neuropathic
symptoms. At the end of treatment she had had a partial
response both by CT and serum CA125 criteria, 186 to
12 U/mL (Figure 2).
Patient 3
65 year old woman with stage 3C grade 3 serous ovarian
cancer in 2007. Four cycles of neoadjuvant carboplatin
AUC 6 and paclitaxel 175 mg/m
2 were administered fol-
lowed by delayed primary surgery. She then received a
further 3 cycles of carboplatin AUC 6 and paclitaxel 175
mg/m
2 (2/2007-9/2007). Partial response was noted on
the end of treatment CT scan. Serum Ca125 started
increasing 4 months following treatment completion
with progressive disease confirmed on CT (1/2008). She
was then commenced on weekly carboplatin AUC 3 and
paclitaxel 75 mg/m
2 4 months after last platinum ther-
apy. She tolerated the first 9 cycles well, however, she
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Figure 1 Patient 1: platelet count (bar graph) and corresponding serum CA 125 (U/ml). Carboplatin AUC 3/paclitaxel 75 mg/m
2 (white
columns). Single agent carboplatin AUC 3 (hatched columns). Dose omission (black columns). Carboplatin AUC 2/paclitaxel 20 mg/m
2 (diagonal
lined column). Carboplatin AUC 3/paclitaxel 20 mg/m
2 (striped column). Carboplatin AUC 4/paclitaxel 20 mg/m
2 (hatched column). Serum CA
125 (solid line).
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Page 3 of 9subsequently developed clinically significant grade 2 per-
ipheral neuropathy and the dose of paclitaxel was
reduced to 20 mg/m
2. The patient had no delays for
haematological toxicity and her peripheral neuropathy
resolved on the reduced dose of paclitaxel (Figure 3).
She completed 18 cycles of treatment following which
CT scan confirmed PR and serum Ca125 decreased
from 891 to 78 U/mL.
Patient 4
52 year old diagnosed in 2008 following suboptimal
debulking surgery for grade 3, stage, 3C serous ovarian
cancer. She developed platinum refractory disease on
restaging CT scan following 3 cycles of carboplatin
AUC 6 and paclitaxel 175 mg/m
2 (6/2008-8/2008). She
also complained of grade 2 peripheral neuropathy. The
patient commenced carboplatin AUC 3 and paclitaxel
20 mg/m
2 weekly. Paclitaxel was omitted for one week
(week 8) for grade 3 arthralgia (solid colour, Figure 4)
and reintroduced in subsequent cycles. She encountered
no delays or dose reductions for toxicity. Furthermore,
her neuropathic symptoms resolved during the course
of her weekly treatment. Whilst an interim assessment
suggested anti-tumour activity, at the end of 18 cycles
the patient had progressive disease on CT examination.
Patient 5
76 year old diagnosed in 2006 with a grade 2, stage 3 ser-
ous adenocarcinoma of primary peritoneal origin following
an omental biopsy. She was deemed to be of high opera-
tive risk because of multiple co-morbidities and received
four cycles of neoadjuvant carboplatin AUC 5 followed by
delayed primary surgery and 3 further cycles of carboplatin
(9/2006-4/2007). She developed progressive disease (10/
2007) and commenced 3-weekly paclitaxel 175 mg/m
2 to
stable disease (10/2007-2/2008). Treatment was compli-
cated by grade 3 peripheral neuropathy. Three months fol-
lowing completion of therapy she developed progressive
disease and commenced on carboplatin AUC 5 in combi-
nation with liposomal doxorubicin 40 mg/m
2 completing
6 cycles (5/2008-11/2008) with a partial response seen on
CT. She experienced disease relapse 6 months later and
was commenced on weekly carboplatin AUC 3 and pacli-
taxel 20 mg/m
2. Therapy was delayed for 2 weeks because
of neutropaenia (week 3 and 4, although there was no
thrombocytopenia) and she was commenced on G-CSF
300 μg days 2-5 with each subsequent cycle. Treatment
was also delayed for 2 weeks for a tooth extraction (weeks
8 and 9). The last two weeks of treatment were omitted as
she developed varicella zoster infection. Her platelet count
and serum CA 125 are shown (Figure 5). Her neuropathic
symptoms did not worsen during the course of treatment.
At the end of 16 cycles the patient had stable disease on
CT examination and serum CA 125 reduced from 465 to
89 U/ml.
Patient 6
57 year old woman with a stage 1A, grade 1 granulosa
cell tumour of the ovary diagnosed following optimal
debulking surgery in 2000. She represented three years
later with recurrent pelvic and peritoneal disease. She
received three cycles of bleomycin, etoposide and cispla-
tin (3/2004-5/2004) however interval CT scan showed
no response to therapy, and she underwent complete
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Figure 2 Platelet count and corresponding corresponding serum CA 125 patient 2. Carboplatin AUC 3/paclitaxel 75 mg/m
2 (white bars).
Dose omission (black columns). Carboplatin AUC 3/paclitaxel 20 mg/m
2 (hatched bars). Serum CA 125 (solid line).
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Page 4 of 9macroscopic debulking. In August 2005 she underwent
further debulking surgery for hepatic and splenic metas-
tases. In September 2008 she developed peritoneal and
hepatic metastases. She commenced 3 weekly carbopla-
tin AUC 6 and paclitaxel 175 mg/m
2 (3/2009-5/2009).
Interval CT scan after 3 cycles of therapy confirmed
progressive disease and she commenced weekly carbo-
platin AUC3 and paclitaxel 75 mg/m
2. Her pre-existing
neuropathy significantly worsened (grade 2) after 7
weekly cycles, and the paclitaxel dose was reduced to
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Figure 3 Platelet count and corresponding corresponding serum CA 125 patient 3. Carboplatin AUC 3/paclitaxel 75 mg/m
2 (white bars).
Carboplatin AUC 3/paclitaxel 20 mg/m
2 (hatched bars). Serum CA 125 (solid line).
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Figure 4 Platelet count of patient 4 treated with weekly carboplatin AUC 3 and paclitaxel 20 mg/m
2 (hatched bars). Single agent
carboplatin AUC 3 (solid bar). Serum CA 125 (U/ml)(solid line).
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Page 5 of 920 mg/m
2. She completed 18 cycles of therapy with no
episodes of thrombocytopaenia and without any further
deterioration in her neuropathic symptoms (Figure 6).
At the end of treatment she had had a partial response
by CT criteria.
Patient 7
Patient 7 was a 57 year old woman diagnosed with a stage
3C serous ovarian cancer following optimal debulking sur-
gery in 2006. She received 6 cycles of adjuvant chemother-
apy, carboplatin AUC 6 and paclitaxel 175 mg/m
2 (10/
2006-2/2007) A year later she developed progressive disease
and received six cycles of carboplatin AUC 6 and gemcita-
bine 1000 mg/m
2 (1/2008-6/2008). In October 2008 she
developed progressive disease and completed six cycles of
liposomal doxorubicin in February 2009 (10/2008-3/2009).
After a PFI of 3 months, she developed progressive disease
and commenced treatment with weekly carboplatin AUC 3
and paclitaxel 75 mg/m
2 June 2009. However her pre-exist-
ing neuropathy significantly worsened (grade 2) after 5
weekly cycles, and the paclitaxel dose was reduced to
20 mg/m
2 (Figure 7). She completed 16 cycles of therapy
with no episodes of thrombocytopenia and without any
further deterioration in her neuropathic symptoms. At the
end of treatment she had had a partial response on CT and
serum CA 125 reduced from 911 to 83 U/ml.
Discussion
Several chemotherapeutic agents such as topotecan,
gemcitabine, liposomal doxorubicin, paclitaxel and eto-
poside have been used in the treatment of platinum-
resistant disease with unexciting response rates in the
range of 6-15% [19-21]. Data previously published by
our group and others suggest that the use of use of
extended dose-dense chemotherapy results in response
r a t e so f4 0 - 6 0 %i nt h i so t h e r w i s ep o o rp r o g n o s i sg r o u p
[22-24]. Extended dose-dense therapy affords the oppor-
tunity to effectively and tolerably treat conventionally
platinum-resistant patients with platinum again. This is
of importance as platinum resistance ultimately becomes
the dominant problem for most patients with ovarian
cancer. It is well established that effective administration
of single agent carboplatin may be compromised by
dose-limiting thrombocytopenia, which may be circum-
vented by the platelet sparing effect of paclitaxel. How-
ever, a limitation in retreating patients with dose dense
combination therapy is the development of peripheral
neuropathy either because of previous taxane therapy or
other co-morbidities such as diabetes mellitus. In this
case series we have shown that the addition of low dose
paclitaxel exerts a platelet sparing effect and does not
worsen the clinical symptoms of peripheral neuropathy,
and did not impact negatively on the dose intensity or
the tumour response to carboplatin. The major limita-
tion of this report is the small samples size with only
seven patients included in this hypothesis generating
study. However the results suggest that this approach
requires further investigation in the form of a formal
randomised phase II study, and would be strengthened
by the inclusion of planned formal nerve conduction
studies in .such a study.
The exact mechanism by which paclitaxel exerts its
platelet sparing effect remains unclear. Pertusini and
colleagues reported that P-glycoprotein-mediated efflux
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Figure 5 Platelet count for patient 5 treated with weekly carboplatin AUC 3 and paclitaxel 20 mg/m
2 (hatched bars) and
corresponding serum CA 125 (U/ml)(solid line). Dose omission (black bars).
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Page 6 of 9of paclitaxel, perhaps in association with glutathione S-
transferase-mediated detoxification of carboplatin,
results in the relative sparing of marrow colony-forming
units-megakaryocytes after exposure to carboplatin and
paclitaxel. Furthermore, the authors report high levels of
circulating serum thrombopoietin in patients receiving
combination therapy which was felt to be derived from
t h em a r r o ws t r o m a .T h ea u t h o r sh y p o t h e s i s et h e r e f o r e
that there is relative sparing of megakaryocytes due to
reduced drug exposure and these cells are then in turn
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2 (white bars).
Carboplatin AUC 3/paclitaxel 20 mg/m
2 (hatched bars). Dose omission (black bars). Serum CA 125.
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2 (hatched bars).
Serum CA 125 (solid line).
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Page 7 of 9stimulated by stromal derived thrombopoietin [25]. As
the mechanism for this protection is not well under-
stood, there are theoretical concerns that this platelet
sparing effect could also protect the tumour. However,
several studies including the combined analysis of the
ICON4/AGO OVAR 2.2 study showed no survival dis-
advantage for the combination arm thereby providing
some reassurance on this issue [26].
In the present case series we demonstrate the clini-
cally platelet protective effect of low dose paclitaxel in
patients receiving dose dense weekly carboplatin. In all
patients the dose of paclitaxel was reduced because of
peripheral neuropathy which did not worsen during low
dose weekly paclitaxel therapy. We did not feel it was
ethical to commence with a low dose of paclitaxel in
patients not previously exposed to this drug because of
the theoretical problem of developing resistance to
paclitaxel. In patient 1, paclitaxel was initially omitted
because of neuropathy and an expected abrupt reduc-
tion in platelets was noted despite a concurrent reduc-
tion in carboplatin dose to AUC2. Low dose paclitaxel
was then introduced. In order to ascertain the maximal
dose of weekly carboplatin that could be administered
with low dose paclitaxel, the dose of carboplatin was
slowly increased to an AUC 4 when the patient then
developed thrombocytopaenia suggesting that AUC 3
was the likely maximal tolerated dose of carboplatin and
this dose was subsequently used in the other six patients
successfully. As indicated in the figures, the majority of
patients received at least 8 weeks of weekly therapy with
maintenance of platelet counts suggesting the utility of
this regimen in this population group.
Based on these results, we suggest that with the
approach of maximal carboplatin dose and low dose
paclitaxel, it may be possible to create an active dose-
dense platinum-focussed “scaffold” that can be used to
feasibly integrate novel agents that target the reversal of
platinum resistance [27]. With the realisation that deli-
vering carboplatin AUC 3 weekly for 18 cycles is achiev-
able and active in platinum resistant disease, a feasibility
study is planned to identify the minimum dose of pacli-
taxel that is platelet-sparing. This strategy seeks to maxi-
mise delivered weekly platinum whilst minimising
paclitaxel related toxicities, thereby maximising “space”
within the scaffold” to absorb potential toxicities of tar-
geted molecular therapies that reverse platinum resis-
tance singly or in combination, since these therapies will
bring their own toxicities to the regimen.
Investigators have recently begun to suggest that the
response in weekly carboplatin and paclitaxel therapy is
principally due to weekly paclitaxel, as judged by the
weekly paclitaxel data [28]. This case series demon-
strates that firstly, dose dense carboplatin is feasible in
carboplatin focussed scaffolds, and secondly, that from
the response profile of these patients, carboplatin given
in this way is highly active even with very low dose
paclitaxel. A potential therapeutic space is to sequence
this approach after patients relapse from weekly pacli-
taxel; there is a rich seam of targeted therapeutics that
m a yb eh i g h l ye f f e c t i v ei nr e v e r s i n ga c q u i r e dp l a t i n u m
resistance in ovarian cancer in this context that require
urgent testing utilising this approach.
Conclusion
In the present case series we have demonstrated that the
addition of low dose paclitaxel allows delivery of weekly
dose dense carboplatin AUC 3 by maintaining platelet
counts without compromising dose dense carboplatin
mediated tumour response. We have shown this regi-
men to be well tolerated and effective, in this otherwise
poor prognostic group. Given the disappointing
responses to non platinum agents in this disease setting
we feel that this regimen merits further investigation as
part of a larger study. We conclude that this regimen is
feasible and active, and could be formally developed as a
“platinum-focussed dose-dense scaffold” into which tar-
geted therapies that reverse platinum resistance can be
incorporated.
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